GLP-1 Drugs and Epilepsy: Do They Affect Seizure Risk? First Large-Scale Analysis | Research

The takeaway

First study examining seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy, addressing a critical safety gap for the growing number of epilepsy patients taking these drugs.

First epilepsy safety data
Initial analysis of seizure recurrence after GLP-1 drug initiation in adults with epilepsy — filling a critical safety gap

What the researchers found

First study examining seizure recurrence after GLP-1 RA initiation in epilepsy patients, providing initial safety data for this growing patient overlap.

Why it matters

Epilepsy and metabolic disease commonly co-occur. Without safety data, clinicians were prescribing GLP-1 drugs to epilepsy patients blindly. This study provides the first evidence base for informed prescribing.

The numbers in context

Study covered January 2003 to August 2025. Patients required 3+ epilepsy diagnoses for inclusion. Multiple GLP-1 drugs were studied: exenatide, liraglutide, dulaglutide, lixisenatide, and others.

How the study worked

Retrospective analysis of seizure recurrence patterns in adults with epilepsy who initiated GLP-1 receptor agonist therapy. Compared pre- and post-GLP-1 seizure rates.

Who was studied

Adults 18+ with epilepsy (3+ diagnoses) and type 2 diabetes who initiated GLP-1 receptor agonists

What this study cannot tell us

Retrospective design. Multiple confounders including weight changes, medication interactions, and variable seizure monitoring. Specific findings need prospective confirmation.

How to read the evidence

Preliminary evidence: first retrospective analysis of an unstudied patient population. Prospective studies needed.

When this study was published

Published in 2025. Addresses a previously unstudied safety question.

The bigger picture

As GLP-1 drugs are prescribed to broader populations, understanding their effects in patients with neurological conditions becomes critical. GLP-1 receptors are expressed throughout the brain, and their activation could theoretically affect seizure threshold in either direction.

Questions still open

Do GLP-1 drugs have pro- or anti-seizure effects through brain GLP-1 receptors?
Should specific GLP-1 drugs be preferred or avoided in epilepsy patients?
Do weight loss and metabolic improvement independently affect seizure control?

Common questions

Can I take GLP-1 drugs if I have epilepsy?

This first study specifically examined this question. While full results are in the paper, the fact that this analysis was conducted at all reflects growing recognition that many epilepsy patients need GLP-1 drugs. Discuss with both your neurologist and endocrinologist.

Could GLP-1 drugs affect seizures?

GLP-1 receptors exist in the brain, so GLP-1 drugs theoretically could affect seizure threshold. This study provides the first data on what actually happens to seizure patterns when epilepsy patients start GLP-1 drugs.

Read the original research

Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.

Epilepsia

View on PubMed ↗Publisher’s paper ↗

Citation

AbuAlrob, Majd A; Hussein, Abdullah; Abdellatif, Rand; Itbaisha, Adham; Zammar, Khaled; Mesraoua, Boulenouar. (2025). Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.. Epilepsia. https://doi.org/10.1111/epi.70022